Costil

Quick links to important sections

Costil

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Costil

What is Costil? Defining the Medicinal Entity

Property Description
Active Ingredient Domperidone
Form Tablets, Oral Suspension
Pharmacological Class Dopamine Receptor Antagonist, Prokinetic Agent
Common Use Relief of Nausea and Vomiting
Origin Synthetic Compound

Costil is a pharmaceutical product whose active ingredient, Domperidone, is officially classified as both a dopamine receptor antagonist and a prokinetic agent. This medication is a synthetic compound, specifically a derivative of benzimidazolone, and is typically designated as a prescription-only medicine (Rx) in various regions, indicating its use requires medical guidance. A differentiating factor for Costil is its availability in an oral suspension form, which facilitates administration for individuals who find swallowing tablets challenging.

The drug's dual classification is central to its intended function. As a dopamine receptor antagonist, Domperidone acts selectively on peripheral D2 receptors, primarily influencing the digestive system and the Chemoreceptor Trigger Zone (CTZ), the area that controls the vomiting reflex. Anti-dopaminergic agents are used to manage specific types of vomiting and nausea. This pharmacological approach is clinically recognized for its ability to suppress the body's signal to vomit.

As a prokinetic agent, the general purpose of Costil is to improve the muscular function of the upper digestive tract. It achieves this by stimulating contractions in the stomach and increasing the tone of the lower esophageal sphincter (LES), thereby accelerating the rate of gastric emptying. Domperidone’s pharmacological mechanism is characterized by the stimulation of smooth muscle and the improvement of motility. This action helps relieve feelings of uncomfortable fullness and pressure often associated with sluggish digestive function. Costil is manufactured as a single-active-ingredient product, available for the oral route of administration.

Regulatory References

  1. Domperidone in National List of Essential Medicines (CDSCO)

What side effects are possible with Costil?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential adverse effects of Domperidone (Costil) based on the frequency of their occurrence and the body system affected. The most significant safety focus is on potential Cardiac Disorders, where serious reactions such as QTc prolongation, Ventricular arrhythmias, and sudden cardiac death have been documented, primarily classified as a Not Known frequency due to post-marketing reporting, but highlighted due to their clinical importance.

Frequency and System Classification

Adverse reactions are formally grouped into categories as defined by regulatory authorities:

  • Common effects (affecting up to 1 in 10 people) typically include dry mouth.
  • Uncommon effects (affecting up to 1 in 100 people) can involve Nervous System Disorders like headache and drowsiness, as well as Gastrointestinal effects like diarrhoea.
  • Endocrine Disorders are documented, including effects related to increased prolactin levels, such as galactorrhoea (uncommon).
  • Very Rare effects (affecting up to 1 in 10,000 people) include allergic reactions and extrapyramidal symptoms.

Safety Constraints and Special Populations

Safety labeling specifies constraints related to dose, duration, and patient health status. The risk of serious cardiovascular events is officially recognized as being associated with higher daily doses (greater than 30 mg) and long-term exposure. Older adults (over 60 years) are identified as a population with a potentially increased risk of serious ventricular arrhythmias. Furthermore, the medication is contraindicated in patients with pre-existing moderate to severe hepatic impairment, known QTc prolongation, or existing cardiac conditions like congestive heart failure. These limitations are put in place to manage risks defined in official regulatory assessments.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is based strictly on the officially documented descriptions of overdose and mandated emergency actions found in government regulatory sources.

Overdosage of the active ingredient in Costil, Domperidone, may result in documented clinical manifestations primarily involving the Central Nervous System (CNS) and cardiovascular systems. Officially listed signs include drowsiness, disorientation, and severe extrapyramidal reactions, which are uncontrolled movements. The risk of these neurological effects is noted to be higher in children.

Severe Outcomes & Risks
Official documents recognize that overdose is associated with the potential for QT interval prolongation on the electrocardiogram (ECG) and the risk of serious ventricular arrhythmias and sudden cardiac death.

Immediate Emergency Action Required:

Regulators mandate that immediate emergency medical attention must be sought if an overdose is suspected. Specifically, medical help must be obtained straight away if symptoms such as irregular heartbeat or fainting occur. Management involves providing standard symptomatic and supportive treatment and requires ECG monitoring due to the identified cardiac risks.

Crucially, regulatory information states that no specific antidote to Domperidone is known. Procedural steps mentioned as potentially useful include gastric lavage and the administration of activated charcoal.

Therapeutic Uses of Costil

What Costil Treats: Main Uses and Benefits

This medication is applied across therapeutic domains where additional symptomatic support is needed in situations where patients experience symptoms related to physical discomfort. Costil is commonly used when symptom clusters that interfere with daily comfort, such as leg pain, aching, or cramping, become more disruptive during flare-ups and are associated with acute or episodic changes. It is relevant when symptoms create noticeable physiological strain and interference with daily functioning. It is applied in scenarios where additional management of discomfort is required, and is considered relevant in conditions involving episodic or fluctuating manifestations.

Easing Leg Pain and Cramping During Activity

This therapeutic domain is relevant for managing symptom clusters that interfere with daily comfort, such as symptoms related to physical discomfort that occur with activity. The medication may assist with easing the overall symptom load during periods when symptoms become more noticeable. This provides support that helps ease the overall symptom burden.

Supporting Functional Stability

The medication is commonly used to help with symptoms that interfere with daily functioning, and supports general well-being during symptomatic phases. This contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Supportive Management for Physical Discomfort During Activity

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The active ingredient in Costil is cilostazol, a medication primarily prescribed to relieve the symptoms of intermittent claudication, which is pain in the legs caused by peripheral arterial disease (PAD).

Costil is intended for use in patients who have not achieved adequate symptom relief from lifestyle changes, such as supervised exercise programs, alone.


Contraindications (Who Should NOT Use Costil)

Cilostazol is an inhibitor of phosphodiesterase III, and similar drugs in this class have been associated with decreased survival in patients with heart failure. Therefore, Costil is strictly contraindicated in patients with:

  • Heart failure of any severity.
  • A history of hypersensitivity or allergic reaction to cilostazol or any other component of the tablets.

Important Warnings and Precautions

Certain conditions require caution or avoidance of Costil due to increased risk of serious adverse events. Patients should not use this medication if they have active pathological bleeding (e.g., bleeding peptic ulcer or intracranial hemorrhage) or an existing hemostatic disorder, as cilostazol inhibits platelet aggregation. Use is also generally avoided in patients with severe hepatic impairment (liver disease) or those taking potent inhibitors of the CYP3A4 or CYP2C19 enzyme systems, which can significantly increase cilostazol levels. Close monitoring is essential for patients with a history of ischemic heart disease due to the risk of exacerbating angina or myocardial infarction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Costil (Domperidone) is defined by specific pharmacokinetic and pharmacodynamic restrictions detailed in government regulatory documents.

Interaction Scope

Interacting Product Categories:

  • Potent inhibitors of the CYP3A4 enzyme
  • QTc-prolonging medicinal products
  • Antacids and Antisecretory Agents

Mechanistic Basis:

  • Pharmacokinetic: Co-administration with potent CYP3A4 inhibitors results in decreased metabolism and a significant increase in Domperidone plasma exposure.
  • Pharmacodynamic: Co-administration with QTc-prolonging medicines creates an additive effect on the cardiac conduction interval, increasing proarrhythmic risk.
  • Bioavailability: Substances that lower gastric acidity (like Antacids) officially reduce the drug's oral bioavailability.

Interaction Restrictions and Constraints

Contraindicated Combinations: Co-administration is strictly contraindicated with potent CYP3A4 inhibitors (such as certain azole antifungals and macrolide antibiotics) and with most QTc-prolonging medicinal products (such as specific antiarrhythmics) due to documented cardiac risk.

Timing-Based Rule: Administration of Antacids or Antisecretory Agents must be separated; they should not be taken simultaneously with this medicine.

Food/Substance Interactions: Taking the oral dose after a meal is documented to enhance bioavailability. The use of Grapefruit Juice is documented to increase systemic exposure.

Mechanism of Action

How Costil Works: Mechanism of Action

The mechanism of action for Domperidone (Costil) is governed by two principal, peripherally selective domains that modulate both digestive movement and the emetic reflex pathway.


Peripheral D2 Receptor Antagonism

This mechanism involves the drug acting as an antagonist to block Dopamine D2 receptors located primarily in the Chemoreceptor Trigger Zone ( CTZ) and the gastrointestinal tract wall. This targeted blockade is a consequence of the drug's limited ability to cross the Blood-Brain Barrier ( BBB), resulting in its activity being concentrated on peripheral signaling systems. By blocking the dopamine signals in the CTZ, the drug inhibits the neuronal signaling sequence that mediates the emetic reflex.


Disinhibition to Enhance GI Motility

The second domain focuses on D2 receptors located on the nerve endings of the enteric nervous system. Dopamine naturally imposes an inhibitory brake on the release of Acetylcholine ( ACh), the key neurotransmitter for muscle contraction. By blocking the D2 receptor, Domperidone removes this brake, leading to a local increase in ACh release. This disinhibition enhances the force and frequency of smooth muscle contractions in the stomach and upper intestine, which results in the accelerated transit of contents and increased Lower Esophageal Sphincter ( LES) tone.

Dosage and Administration Information

How to Use Costil

Costil (Domperidone) administration is based on the principle of using the lowest effective dose for the shortest duration necessary, typically not exceeding seven days. This approach ensures standardized use aligned with prescribing information, focusing on the procedural structure of its intake.


Administration Scope and Dosing

Instruction Detail
Route of Administration Primarily the oral route (tablets, suspension, orodispersible tablets); the rectal route (suppositories) may also be used.
Standard Adult Dose 10 mg per dose.
Maximum Daily Dose 30 mg per day (not to be exceeded).
Frequency Up to three times daily (TID).
Timing Recommended to be taken before meals (pre-meal), as food can delay its absorption.
Missed Dose Rule If a dose is missed, it should be omitted, and the patient should resume the next scheduled dose; the dose should not be doubled to compensate.

Specific Use Instructions

The dosage for this medicine requires careful adjustment in certain populations. For patients with severe renal impairment, the dosing frequency must be reduced, such as taking the dose once or twice daily, depending on the severity of kidney function.

In pediatric patients weighing less than 35 kg, the tablets and suppositories are generally unsuitable due to the necessity of accurate, weight-based liquid dosing (e.g., 0.25 mg/kg up to three times daily). The tablets (10 mg) are typically reserved for adolescents weighing 35 kg or more.

Recent Clinical Evidence

Research Evidence Overview of Studies for Costil

The clinical evaluation of Costil (Domperidone) has primarily focused on the digestive tract and what research has explored regarding the vomiting reflex. The evidence base includes various types of studies, such as Randomized Controlled Trials (RCTs) and comprehensive systematic reviews, which are relevant in trials assessing short-term or episodic symptom patterns. The findings described reflect group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain—about this medication.


Evidence for Use in Acute Nausea and Vomiting

Research for this use has primarily involved short-term RCTs which were applied in studies examining patient-reported experiences related to outcomes related to the measured change in the frequency of vomiting and the severity of nausea. These studies focused on populations of adults and adolescents experiencing acute symptoms, such as those related to acute gastroenteritis or chemotherapy-induced symptoms. The research describes the tracking and measurement of the frequency of vomiting episodes as the primary data point in groups receiving the study medication.

However, the evidence remains limited regarding the effects of continued use beyond the recommended short-term window. Research exploring how symptoms change over time past the acute phase is not well-characterized, and long-term effects are not fully established.


Evidence for Use in Chronic Symptoms of Functional Dyspepsia

Costil was evaluated in research exploring symptoms of functional dyspepsia, a chronic condition characterized by feelings of uncomfortable fullness, early satiety, and bloating. Studies for this indication often involved intermediate observation periods, usually lasting several weeks. Studies report how symptoms evolved in the observed populations; however, findings were mixed across studies, particularly when looking at specific symptoms like epigastric pain. Certainty remains low, and some scientific reviews indicate that the reported outcomes were not considered conclusive enough for use in this prolonged condition.


What Remains Unstudied and Uncertain

A key limitation across the research landscape is the duration of observation. Follow-up durations were limited, leaving long-term effects not fully established. Similarly, comparative evidence is lacking, as many trials focused on comparison against placebo or standard care, and findings were mixed. The evidence is limited in determining the full range of outcomes related to systemic or functional imbalance over extended periods.

Key Studies & References

  1. Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis
  2. Efficacy and Safety of Domperidone in Combination with Proton Pump Inhibitors in Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Costil (FAQ)


Q: How quickly can someone expect to notice the effects of Costil?

Official product information indicates that the medicine is rapidly absorbed following oral intake. Maximum concentration in the bloodstream is reported to occur in about one hour after a dose. Regulatory documents indicate that its absorption is affected by food, and official instructions for administration typically mention taking it before a meal.


Q: What is the difference between Costil and generic alternatives?

Costil contains the active ingredient Domperidone. Regulatory documentation confirms that while the active ingredient must be the same, inactive ingredients (such as binders or coloring) can vary between the brand name product and its generic alternatives. The specific composition is detailed in the patient information provided with the product.


Q: Can Costil interact with common pain relievers like ibuprofen?

Common non-prescription pain relievers like ibuprofen are typically not classified in official documents as strong inhibitors of the CYP3A4 enzyme or QTc-prolonging agents. Official documents outline the most significant interaction risks by mechanism, and all concomitant medication use requires review.


Q: How long does Costil typically stay in the body?

The time it takes for the concentration of the active ingredient to drop by half (known as the terminal plasma half-life) is generally reported to be between 7 and 9 hours in healthy adults. However, this time may be prolonged in individuals who have severe kidney impairment, so a longer duration should be considered in those cases.


Q: Can Costil be taken by people who have a history of high blood pressure?

The primary safety constraints relate to cardiac risk, including known QTc prolongation or existing cardiac diseases such as congestive heart failure. Official documents do not typically list high blood pressure as a direct contraindication, but underlying heart conditions are constraints for use.


Q: Can Costil interact with herbal supplements?

Regulatory guidance indicates that information on interactions with herbal supplements is often limited. Official documents note that all concomitant product use is relevant for review.


Q: Do many people report feeling tired when using Costil?

Drowsiness and headache are officially classified as 'Uncommon' side effects in product information, meaning they may affect up to 1 in 100 people. This means these effects are considered less frequent compared to the most 'Common' reported side effect, which is dry mouth.


Q: Can Costil be crushed or split?

Official administration instructions for the tablet formulation do not include directions for physically altering the medicine, such as crushing or splitting it. The product is available in multiple forms, including an oral suspension, which is designed for individuals who require liquid dosing.


Q: Does Costil interact with contraceptive pills?

The active ingredient in this medicine is processed by the CYP3A4 enzyme system in the body. Although hormonal contraceptives are not typically listed as strictly prohibited, any medicine that interacts with the CYP3A4 pathway is considered relevant for professional review.


Q: Is Costil the same type of medicine as [similar drug name]? (high-level comparison)

Costil's active ingredient, Domperidone, is officially classified as a peripheral Dopamine D2 receptor antagonist and a prokinetic agent. This classification defines the drug’s category based on its mechanism of action, which focuses on modulating nerve signals and stimulating muscular function in the digestive tract.


Q: Can Costil affect sleep patterns?

Official reports indicate that insomnia, or difficulty sleeping, has been documented as a potential event. This has been noted, particularly in cases where the medication was discontinued suddenly or tapered, and is listed as a potential effect related to its use.


Q: What happens if Costil is taken after its expiration date?

Official governmental guidance states that the medicine should not be used past the expiration date. Disposal instructions typically state that expired or unused medication should be returned through a pharmacy take-back program.


Q: Why is Costil categorized as a Schedule [X] drug?

The medicine is generally classified as a Prescription-Only Medicine (Rx) by regulatory authorities in many regions. This status is often assigned due to the potential for serious cardiac side effects, which requires clinical monitoring and oversight.


Q: Does Costil affect alertness or the ability to concentrate?

Official product information carries warnings that the medicine may cause certain effects, such as dizziness or drowsiness. Official warnings state that patients experiencing these effects should avoid activities such as driving or operating machinery.


Q: Are headaches a common concern when taking Costil?

Headache and migraine are listed as 'Common' side effects in the official product information. This means that these effects have been reported to affect up to 1 in 10 people who use the medication.


Q: Are there different forms (tablet, liquid, etc.) of Costil available?

Yes, regulatory documents note that the drug is available in multiple forms, typically including tablets and an oral suspension. Other forms, such as orodispersible tablets or suppositories, may also be available depending on the specific region and its authorized formulations.


Q: Is Costil used in children?

Official authorization for the relief of nausea and vomiting is now restricted to adults and adolescents aged 12 years or older and weighing 35 kg or more. The medicine is generally not licensed for this specific indication in children younger than 12 years old.


Q: What are the signs of an allergic reaction to Costil?

Signs that may indicate a serious allergic reaction include sudden and severe swelling of the lips, mouth, throat, or tongue, as well as difficulty breathing or swallowing. A severe rash is also a possible sign. These effects are considered rare; however, signs of a serious allergic reaction are generally viewed as clinical emergencies.


Q: Is Costil a newer or older medicine?

The active ingredient, Domperidone, was first developed in 1974 and was introduced for medical use around 1979. This indicates that the medicine has been available for clinical use for several decades.


Q: Are there any genetic factors that affect how Costil works?

Scientific studies have investigated how differences in certain genes, specifically those involved in drug metabolism (like CYP2D6) or transport, may influence how the body processes the medication. These genetic factors may impact the amount of drug in the body and the potential for side effects.


Q: How often do official sources update information about Costil?

Regulatory bodies continuously monitor the medicine's safety profile throughout its life cycle. They periodically issue Drug Safety Updates or Safety Reviews as new information or risk-benefit data becomes available, which leads to updates in the official product information documents.


Q: Why do some forums discuss a rare side effect of Costil?

The regulatory classification of highly serious but rare side effects, such as sudden cardiac death, is often listed as 'Not Known' (very rare) because they are identified through post-marketing surveillance. These infrequent but critical reports form the basis for official warnings, which are then commonly discussed among users.


Q: What specific conditions must be met for someone to be eligible for Costil?

The medicine is officially authorized for the relief of symptoms of nausea and vomiting. Its use is restricted to a short duration, typically no more than seven days. Additionally, certain existing cardiac or severe liver conditions are listed as contraindications in the official product information.


Q: Is Costil ever taken on an 'as-needed' basis?

The medicine is generally prescribed as a structured regimen, typically up to three times daily for the shortest possible duration, as authorized in the product information.

How should Costil be stored and disposed of?

Storage and Disposal Requirements for Costil (Domperidone)

Official regulatory documents define strict conditions for storing and discarding this medicine to ensure its stability and safety.

Required Storage Conditions

Costil (Domperidone) must be stored at a controlled room temperature, typically required not to exceed 25 C or 30 C depending on the formulation and region. The product must be actively protected from light and moisture and should be stored in its original, tightly closed package. A mandatory handling rule is to keep the medicine from freezing.

Disposal and Child Safety

For safety, the medicine must be kept out of the sight and reach of children at all times. Regulatory instructions prohibit throwing unused or expired Costil into household trash or disposing of it via wastewater. Instead, the drug must be returned through a pharmacy take-back program or an approved chemical waste facility.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Costil found in:

A-Z Index: